Further RISE’ing to the Challenge of Type 2 Diabetes in Youth

Diabetes Care 2021;44:1934–1937 | https://doi.org/10.2337/dci21-0023

Klara R. Klein and John B. Buse

Despite three decades of increasing prevalence of type 2 diabetes (T2D) in adolescents (1), the diabetes community continues to grapple with the pathophysiology of youth-onset T2D. Accumulating evidence indicates that when compared with T2D in adults, T2D in youth follows a more aggressive course (2–4). Adolescents are therefore entering adulthood with an advanced and perhaps misunderstood disease that puts them at risk for morbidity from micro- and macrovascular complications. Moreover, as the susceptibility of individuals with diabetes to poor outcomes during the coronavirus pandemic became increasingly apparent (5), the urgency to address the health crisis of T2D in youth has been amplified.

The Restoring Insulin Secretion (RISE) study, designed in 2014, tested interventions in both adolescents and adults to determine whether β-cell decline could be halted in people with prediabetes or early T2D (6). The primary analyses were overall disheartening regarding slowing the progression of T2D in youth (7–12). However, the RISE study provides the most direct opportunity yet to examine differences between T2D in youth and adults. In this issue of Diabetes Care, the RISE Consortium delivers three articles that offer mechanistic insights into the pathogenesis of T2D and potentially a path forward for the treatment of T2D in youth (13–15). A summary of these articles is presented in Table 1 and discussed in subsequent paragraphs.

RISE was predicated on the critical role of progressive β-cell decline in the pathogenesis of T2D, where β-cell dysfunction results in excessive glucose and fatty acid exposure, termed glucolipotoxicity (6). Glucolipotoxicity coupled with insulin resistance compounds β-cell stress and contributes to β-cell failure. Previous data in adults suggest that early intensive intervention may delay β-cell dysfunction and slow the course of T2D (16–18). Prior to RISE, no study had directly tested this hypothesis in youth or performed a head-to-head comparison between youth and adults with similar levels and duration of dysglycemia.

The RISE study design has previously been described (6). RISE utilized three protocols in participants with impaired glucose tolerance (IGT) or recent-onset T2D. Whereas adults were glucose-lowering medication naive, children with diabetes were eligible if they had been on metformin for <6 months or insulin for <2 weeks. Each group underwent similar assessments at specific time points to provide direct comparisons of the interventions. Adults in the medication cohort were randomized to placebo, metformin, liraglutide + metformin (L+M), or glargine for 3 months followed by metformin (G/M). Adults in the surgical intervention arm received laparoscopic gastric band surgery (LB) or metformin. In children, the intervention compared G/M with metformin alone. In adults, active treatment, including LB, produced improvements in glycemia, but L+M provided the most benefit for β-cell function (10,11). On-treatment improvements observed in adults dissipated within 3 months of washout from medical intervention (10). Conversely, in children with IGT or T2D, neither metformin nor G/M prevented worsening of β-cell function (7,12). The big questions thus remained: why do children have such aggressive decline in β-cell function, and can this decline be prevented? The secondary analyses published in this issue characterize the individuals at most risk for β-cell decline and test the hypothesis that α-cell dysfunction contributes to the rapid deterioration of β-cells in youth.

Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, NC

Corresponding author: John B. Buse, john_buse@med.unc.edu

This article is part of a special article collection available at https://care.diabetesjournals.org/collection/the-RISE-study-more-insights-into-T2D-in-youth-and-adults.

© 2021 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.

See accompanying articles, pp. 1938, 1948, and 1961.
The first report compares the glycemic worsening between youth and adult RISE participants to identify baseline characteristics that predict worsening in each group at the end of the treatment period (month 12) and 9 months following withdrawal (month 21) (13). Treatment did not impact glycemic worsening in youth, 17.8% and 36.7% of whom experienced a 0.5% increase in HbA1c from baseline at month 12 and month 21, respectively. Only 7.5% of adults worsened while on treatment, primarily driven by placebo treatment (14.3% progression). Following withdrawal of intervention, 20% of adults had glycemic worsening. Subjects randomized to L+M experienced attenuated glycemic worsening at month 12 but only demonstrated a trend toward improvement after withdrawal. In both adults and
youth, lower baseline clamp- and oral glucose tolerance test–derived β-cell responses predicted glycemic worsening. Interestingly, though insulin sensitivity predicted progression in adults, it did not predict progression in children. While it is not clear why insulin sensitivity in youth was not predictive, the significantly increased baseline insulin resistance observed in youth likely plays a role. The RISE authors hypothesize that because of the severe insulin resistance observed in youth, β-cell function acts as the key factor to differentiate children who will develop diabetes. Indeed, in the setting of such severe insulin resistance, perhaps modest increases in insulin sensitivity make little difference.

The other two reports examine the role of the α-cell. Prior RISE data demonstrate that at every matched degree of insulin sensitivity, youth release greater amounts of C-peptide and insulin than adults. The RISE Consortium thus concluded that youth have hyperresponsive β-cells (8,9), though the mechanisms surrounding this enhanced insulin release are not understood. α-cell dysfunction and resultant glucagon dysregulation have been accepted as a plausible culprit, due to glucagon effects on the β-cell. Therefore, glucagon levels were assessed to determine whether α-cell dysfunction in youth compared with adults accounted for the β-cell hyperresponsiveness. Unexpectedly, fasting and steady-state glucagon were not different between youth and adults at baseline (14). Fasting glucose and glucagon were positively correlated in adults but trended toward a negative correlation in youth. These data indicate that α-cell dysfunction cannot account for the hyperresponsiveness of the β-cell but also emphasize potential pathophysiologic differences between adults and children.

No change in fasting or steady-state glucagon was observed following treatment with metformin or G/M in youth (15). Thus, while β-cell function declines rapidly in children, α-cell function appears to be preserved. The trajectories of these two cell types have been thought to be parallel, due to proximity and paracrine regulation. These data suggest that, at least in youth, the fates of these cell types are not as connected as hypothesized.

Adults also showed no improvement in α-cell function with metformin, G/M, or placebo. However, L+M and LB demonstrated durable reductions in fasting and steady-state glucagon levels. But adjustments for baseline and change in weight eliminated any difference in fasting glucagon concentration across the treatment subgroups. Adjustments for insulin sensitivity did not impact the results. The importance of weight loss for α-cell function observed in adulthood thus must be acknowledged. Interventions that induce weight loss were not attempted in children.

With sequential and frequent measures of glucose response and insulin sensitivity, the RISE study has provided substantial mechanistic data. Regardless, direct comparison of adults and children will always be fraught with confounders. It is impossible to account for social, epigenetic, and age-related differences between youth and adulthood. However, the degree of insulin resistance at baseline for youth and adults stands out as a major difference. Statistical adjustments for insulin resistance cannot account for all concurrent pathophysiologic effects. Fundamentally one must wonder: are we comparing apples to oranges? Diabetes in youth is different from diabetes in adults.

There is little way to get around these issues, and, thus, making observations and understanding their caveats are essential. RISE offers us the first formal prospective randomized trial to directly compare parameters of α- and β-cells at baseline and in the setting of common interventions in adults and youth. Thus far, RISE reminds us that β-cell function remains the most important marker of risk for diabetes in youth in the setting of severe insulin resistance. Addressing insulin resistance seems paramount to the treatment of T2D in the vulnerable youth. Without addressing peripheral resistance, it seems likely that no matter the intervention, β-cell stress will lead to eventual β-cell failure.

Longitudinal studies, like RISE, are essential for identifying the most vulnerable. Given that puberty is such a tenuous period, pinpointing the most specific parameters for progression to diabetes may allow for early and aggressive intervention. Perhaps, if β-cell function is protected during puberty, T2D onset could be significantly delayed. These are the questions that must be answered in order to protect youth from poor long-term outcomes.

Interventions in adults provide some hope. Surgical or medical weight loss with liraglutide or LB improve many parameters. More aggressive weight loss interventions in youth should be explored. Liraglutide has been shown to be safe and effective in children (19). Metabolic surgery has an evolving role in youth (20). Novel pharmaceuticals under development provide for outstanding reductions in weight. The optimal timing of intervention is also likely to be very different in youth and adults. In youth, intervention prior to puberty might be essential, but we must first understand on whom to intervene. It will be interesting to see what, if any, impact GLP-1 receptor agonists and near-at-hand related medications have on progressive β-cell decline in youth and whether surgical approaches in the very young provide extended protection from T2D.

Designing the right experiment to understand youth T2D pathophysiologically is an incredible challenge. Adult T2D serves as guide, and though the diseases mirror each other, youth-onset T2D has unique characteristics. Further analysis from RISE will undoubtedly provide additional insights (21). Progress remains slow, but with well-designed and executed studies like RISE, understanding accumulates and the path toward effective intervention in youth with T2D becomes clearer.

Funding. J.B.B.’s effort for this work was supported by grants from the National Institutes of Health (UL1TR002489, P30DK124723).

Duality of Interest. J.B.B.’s contracted consulting fees and travel support for contracted activities are paid to the University of North Carolina by Adocia, Novo Nordisk, Senseonics, and vTv Therapeutics in addition to grant support from DexCom, NovaTarg, Novo Nordisk, Sanofi, Toleron, and vTv Therapeutics. J.B.B. is also a consultant to Anji, AstraZeneca, Boehringer Ingelheim, Cirus Therapeutics, Eli Lilly, Fortress Biotech, Janssen, Mellitus Health, Moderna, Pendulum Therapeutics, Praetego, Stability Health, and Zealand Pharma. He holds stock/options in Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego, and Stability Health. No other potential conflicts of interest relevant to this article were reported.

References
1. Dabelea D, Bell RA, D’Agostino RB Jr, et al.; Writing Group for the SEARCH for Diabetes in
Youth Study Group. Incidence of diabetes in youth in the United States. JAMA 2007;297:2716–2724
2. TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 2013;36:1749–1757
3. Zeitler P, Hirst K, Pyle L, et al.; TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366:2247–2256
4. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–2443
5. Gregory JM, Slaughter JC, Duffus SH, et al. COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 diabetes. Diabetes Care 2021;44:526–532
6. RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care 2014;37:780–788
7. RISE Consortium. Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care 2018;41:1717–1725
8. RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. Observations using the hyperglycemic clamp. Diabetes Care 2018;41:1696–1706
9. RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes. II. Observations using the oral glucose tolerance test. Diabetes Care 2018;41:1707–1716
10. RISE Consortium. Lack of durable improvements in β-cell function following withdrawal of pharmacological interventions in adults with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care 2019;42:1742–1751
11. Xiang AH, Trigo E, Martinez M, et al.; RISE Consortium; RISE Collaborators. Impact of gastric banding versus metformin on β-cell function in adults with impaired glucose tolerance or mild type 2 diabetes. Diabetes Care 2018;41:2544–2551
12. RISE Consortium; RISE Consortium Investigators. Effects of treatment of impaired glucose Tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on β-cell function: comparison of responses in youth and adults. Diabetes 2019;68:1670–1680
13. Sam S, Edelstein SL, Arslanian SA, et al.; RISE Consortium. Baseline predictors of glycemic worsening in youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes in the Restoring Insulin Secretion (RISE) study. Diabetes Care 2021;44:1938–1947
14. Kahn SE, Mather KJ, Arslanian SA, et al.; RISE Consortium. Hyperglucagonemia does not explain the β-cell hyperresponsiveness and insulin resistance in dysglycemic youth compared with adults: lessons from the RISE study. Diabetes Care 2021;44:1961–1969
15. Kahn SE, Edelstein SL, Arslanian SA, et al.; RISE Consortium. Effect of medical and surgical interventions on α-cell function in dysglycemic youth and adults in the RISE study. Diabetes Care 2021;44:1948–1960
16. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319–328
17. Kitabchi AE, Temprosa M, Knowler WC, et al.; Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005;54:2404–2414
18. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753–1760
19. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al.; Ellipse Trial Investigators. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med 2019;381:637–646
20. Pratt J, Browne A, Browne NT, et al. ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surg Obes Relat Dis 2018;14:882–901
21. Buse JB, D’Alessio DA, Riddle MC. Can we RISE to the challenge of youth-onset type 2 diabetes? Diabetes Care 2018;41:1560–1562